Teva Pharmaceutical Industries (NYSE:TEVA) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Teva Pharmaceutical Industries (NYSE:TEVA) released its quarterly earnings data on Tuesday. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.72 by $0.14, FiscalAI reports. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. The firm had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same quarter in the previous year, the company posted $0.78 earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis.

Here are the key takeaways from Teva Pharmaceutical Industries’ conference call:

• Teva raised its 2026 guidance, including revenue to $16.7–$17.0 billion and free cash flow to $2.1–$2.4 billion, supported by strong growth in AUSTEDO, AJOVY, and UZEDY. Non-GAAP EPS rose 10% year over year to $0.86, while gross margin expanded to 58.7%.
• The innovative portfolio continued to accelerate: AUSTEDO reached its $2.5 billion sales target a year early, UZEDY revenue increased 96% to $85 million, and AJOVY revenue rose 61% to $269 million. Teva raised full-year product outlooks for all three brands and expects continued long-term growth.
• FDA approval of WELTRUZA, a once-monthly long-acting olanzapine injection, expands Teva’s neuroscience franchise; management expects limited revenue in the first half of 2027 while payer coverage is established, with more meaningful contribution in the second half. Teva estimates the combined UZEDY/WELTRUZA franchise can reach $1.5–$2.0 billion in peak sales.
• Biosimilars are becoming a major growth engine, with Teva achieving its $800 million 2027 sales target a year early and expanding to 15 marketed products plus a broader pipeline. The company also reached investment-grade ratings from all three major agencies and remains on track for net debt leverage of approximately 2x EBITDA by the end of 2027.
• Generic revenue declined 16%, primarily because of lower generic REVLIMID contribution, and AUSTEDO is expected to decline year over year in Q4 due to purchasing patterns and pricing pressure ahead of IRA implementation. Separately, Teva discontinued the emrusolmin Phase II study after a futility analysis, although management reported no safety concerns.

Teva Pharmaceutical Industries Stock Up 1.2%

Shares of TEVA stock traded up $0.51 during trading hours on Wednesday, reaching $42.42. The company had a trading volume of 2,602,401 shares, compared to its average volume of 6,781,310. The company has a market cap of $49.43 billion, a price-to-earnings ratio of 70.94, a price-to-earnings-growth ratio of 3.77 and a beta of 0.97. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. Teva Pharmaceutical Industries has a 12 month low of $22.70 and a 12 month high of $43.34. The business has a fifty day simple moving average of $39.24 and a 200-day simple moving average of $34.64.

Wall Street Analysts Forecast Growth

A number of analysts have commented on TEVA shares. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Leerink Partners started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price objective on the stock. Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. HC Wainwright initiated coverage on shares of Teva Pharmaceutical Industries in a report on Monday. They set a “buy” rating and a $52.00 price objective for the company. Finally, TD Cowen initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, October 1st. They set a “buy” rating and a $55.00 target price for the company. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $46.54.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the transaction, the insider directly owned 8,500 shares in the company, valued at $330,225. This represents a 46.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q3 results topped expectations. Teva reported adjusted EPS of $0.86 versus the $0.72 consensus and revenue of about $4.39 billion versus $4.23 billion. The company also raised its full-year guidance. Revenue was still down 1.9% year over year, tempering the beat. Reuters: Teva Q3 results
• Positive Sentiment: UZEDY growth accelerated. U.S. third-quarter net sales of the long-acting schizophrenia treatment reached $85 million, up 96% year over year. Teva raised its 2026 revenue outlook for the drug to $290 million–$310 million from $270 million–$290 million. UZEDY sales and outlook
• Positive Sentiment: Expanded biosimilar portfolio. Teva secured U.S. commercialization rights to two FDA-approved immunology biosimilars from Samsung Bioepis, with ETICOVO rights expected upon closing and infliximab-abda rights in Q3 2027. The deal could broaden Teva’s products and revenue sources. Teva-Samsung agreement
• Positive Sentiment: Management sees further growth. Teva said it expects stronger growth in 2027 despite the impact of U.S. drug-pricing rules on Austedo, which may help reassure investors about its growth trajectory. Reuters: Teva’s 2027 outlook
• Negative Sentiment: Emrusolmin trial ended for lack of efficacy. Teva discontinued its Phase 2 TOPAS-MSA study after an interim analysis indicated a low likelihood of meeting the primary efficacy goal. The company reported no safety concerns; the decision nevertheless removes a clinical development opportunity. Trial discontinuation and UZEDY outlook

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.